Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a research report released on Tuesday,RTT News reports. They currently have a $48.00 target price on the stock, up from their prior target price of $44.00.

KNSA has been the subject of several other reports. TD Cowen initiated coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Citigroup lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Kiniksa Pharmaceuticals International Trading Down 2.9%

Shares of KNSA opened at $39.43 on Tuesday. The firm has a market cap of $2.92 billion, a P/E ratio of 986.00 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 12-month low of $17.82 and a 12-month high of $42.05. The company’s 50-day moving average price is $36.69 and its 200 day moving average price is $30.78.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company’s revenue was up 61.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.18) earnings per share. Equities research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Sanj K. Patel sold 121,248 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $38.90, for a total transaction of $4,716,547.20. Following the completion of the transaction, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at approximately $4,348,786.60. The trade was a 52.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Eben Tessari sold 138,614 shares of the company’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total value of $4,601,984.80. Following the completion of the transaction, the chief operating officer directly owned 49,915 shares of the company’s stock, valued at $1,657,178. This trade represents a 73.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 905,298 shares of company stock valued at $32,343,574. Corporate insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP boosted its holdings in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Kiniksa Pharmaceuticals International by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 22.6% in the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after purchasing an additional 233,668 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.